Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Next

Ozlem Tureci, the co-founder of BioNTech, hopes to apply the company's SARS-CoV-2 vaccine success to its initial work developing cancer vaccines, the Associated Press reports.

It adds that, with the pandemic, Tureci and Ugur Sahin, her husband and BioNTech co-founder, switched from working on cancer vaccines to one for SARS-CoV-2. As the AP notes, the Pfizer-BioNTech SARS-CoV-2 vaccine received authorization in the UK and US less than a year later.

"It pays off to make bold decisions and to trust that if you have an extraordinary team, you will be able to solve any problem and obstacle which comes your way in real time," Tureci tells the AP. It adds that among the problems BioNTech faced were conducting large, global clinical trials and ramping up manufacturing.

The AP says BioNTech can use the experience and funds it now has for its cancer vaccine research. Tureci tells it that they have a number of mRNA-based cancer vaccines in the works and expects that they may be able to give them to patients in a few years.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.